This is a continuation of this month’s #PharmToExamTable question about C. difficile treatment: What is the evidence supporting a tapered vancomycin regimen?
-Answered by Andre Wilt, PharmD 2020 Graduate of UNMC College of Pharmacy (Reviewed by Scott Bergman PharmD and Andrew Watkins PharmD)
This month’s #PharmToExamTable question was a review of Clostridioides difficile treatment guidelines:
-Answered by Andre Wilt, PharmD 2020 Graduate of UNMC College of Pharmacy (Reviewed by Scott Bergman PharmD and Andrew Watkins PharmD)
The following is a clinical review written by Corey Paz, PharmD. Recent graduate of UNMC College of Pharmacy and new PGY1 Pharmacy Resident at Gunderson Health System in LaCrosse, Wisconsin. Follow him on Twitter @coreypaz. Corey was supervised by Scott Bergman, PharmD, FCCP, FIDSA, BCPS. Pharmacy Coordinator for Antimicrobial Stewardship at Nebraska Medicine and Clinical Associate Professor in the UNMC Dept of Pharmacy Practice and… Continue Reading
Dr. Kimberly Scarsi recently published an important study in Lancet HIV: “Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.” We were excited to learn more about and feature her work! Could you please give us a brief summary of the study you performed? This was a pharmacokinetic evaluation of the effect of antiretroviral therapy (ART) on vaginally administered hormones. Overall, 84 women… Continue Reading
Recently, several of our HIV pharmacist colleagues in our Division of Infectious Diseases at UNMC/Nebraska Medicine, published an invited review in Clinical Pharmacokinetics entitled: Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review. The first author, Dr. Josh Havens PharmD, wrote this summary describing the review article. What prompted the review? This was an invited review, but there was only one previously completed shortly after… Continue Reading
The following is a clinical review written by Lauren Hoeft, PharmD, a recent graduate of the UNMC College of Pharmacy, and supervised by Scott Bergman PharmD FIDSA, Clinical Pharmacy Coordinator of Nebraska Medicine Antimicrobial Stewardship Program Does methenamine prevent recurrent urinary tract infections (UTIs)? Urinary tract infections (UTIs) are one of the most common indications for the use of antibiotics. A UTI is diagnosed not… Continue Reading
The following is a clinical review written by Ashleigh Grammar, PharmD, a recent graduate of the UNMC College of Pharmacy, and supervised by Scott Bergman PharmD FIDSA, Clinical Pharmacy Coordinator of Nebraska Medicine Antimicrobial Stewardship Program (@bergmanscott) What is persistent MRSA bacteremia and how is it treated? Methicillin-resistant Staphyloccous aureus (MRSA) (photo credit: CDC Public Health Image Library) is a bacteria that can cause a wide variety… Continue Reading
The following is a clinical review written by Allison Graner, UNMC College of Pharmacy PharmD candidate 2019, and supervised by Scott Bergman PharmD FIDSA, Clinical Pharmacy Coordinator of Nebraska Medicine Antimicrobial Stewardship Program What is the appropriate treatment for urinary tract infection caused by Candida glabrata? Infections caused by the fungus known as Candida, the most common fungus to be cultured in the microbiology lab… Continue Reading
The Department of Health and Human Services HIV guidelines panel currently recommends antiretroviral therapy (ART) consisting of two nucleoside reverse transcriptase inhibitors plus an integrase inhibitor for most treatment naïve HIV infected individuals1. Prior to the advent of integrase inhibitors, the utilization of non-nucleoside reverse transcriptase inhibitor (NNRTI) based regimens had been common. Both efavirenz and rilpivirine had been commonly used although both NNRTI’s present… Continue Reading
Pharm To Exam Table: Dual Antiretroviral Therapy with Dolutegravir + Lamivudine Currently, triple therapy regimens constituted with a two nucleoside reverse transcriptase inhibitor backbone and anchored by an integrase inhibitor has been the standard treatment for HIV infection. However, these conventional therapies are being challenged due to their long-term side effects. Dual therapy regimens were recently introduced with the first comprising of dolutegravir (DTG)/rilpivirine (RPV)…. Continue Reading
